Disease · MONDO_0002928
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 19 of 19
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03783949 | European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | Phase 2 | 122 | 2025-06-11 | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | CARBOPLATIN, GANETESPIB, GEMCITABINE, NIRAPARIB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT03395080 | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma | Phase 2 | 111 | 2023-06-09 | Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma | DKN-01, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00478426 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | Phase 2 | 34 | 2020-02-17 | Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7, Uterine Carcinosarcoma, Uterine Corpus Carcinosarcoma | SUNITINIB MALATE | Its record names the disease | ClinicalTrials.gov |
| NCT04513665 | ZW25 in Women With Endometrial Cancers | Phase 2 | 16 | 2024-10-21 | Endometrial Cancer, Carcinosarcoma | ZANIDATAMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01061606 | Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus | Phase 2 | 8 | 2016-11-09 | Recurrent Uterine Sarcoma, Uterine Carcinosarcoma | TEMSIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | Phase 3 | 640 | Endometrial Cancer | SACITUZUMAB GOVITECAN | Its record names the disease | ClinicalTrials.gov | |
| NCT00002546 | Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus | Phase 3 | 216 | Sarcoma | CISPLATIN, IFOSFAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04065269 | ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss | Phase 2 | 174 | Gynaecological Cancers | CERALASERTIB, DURVALUMAB, OLAPARIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00003128 | Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus | Phase 3 | 166 | Sarcoma | FILGRASTIM, IFOSFAMIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib | Phase 2/3 | 138 | Ovarian Carcinosarcoma, Endometrial Carcinosarcoma | DOSTARLIMAB, NIRAPARIB | Its record names the disease | ClinicalTrials.gov | |
| NCT06940349 | Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors | Phase 1/2 | 100 | Solid Tumors Refractory to Standard Therapy | PALBOCICLIB, SUNITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT02993705 | Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) | Phase 2 | 45 | Carcinosarcoma, Ovarian, Carcinosarcomas Uterine | TRABECTEDIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05265793 | Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma | Phase 2 | 45 | PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma, Carcinosarcoma | CAMRELIZUMAB, RIVOCERANIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05224999 | Nivolumab for Recurrent/Metastatic Carcinosarcoma | Phase 2 | 28 | Recurrent/Metastatic Carcinosarcoma | NIVOLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05156268 | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | Phase 2 | 26 | Endometrial Carcinosarcoma | OLAPARIB, PEMBROLIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01454479 | A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma | Phase 1 | 24 | Recurrent Endometrial Cancer | IXABEPILONE, LAPATINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03935256 | Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer | Phase 2 | 24 | Endometrial Cancer | CARBOPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT03933761 | Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy | Phase 2 | 0 | Ovarian Cancer, Carcinosarcoma | PAMIPARIB | Its record names the disease | ClinicalTrials.gov | |
| NCT04149275 | Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma | Phase 2 | 0 | Carcinosarcoma of Ovary, Carcinosarcoma of Uterus, Carcinosarcoma of Vagina | CABOZANTINIB, IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002928/trials